Latanoprostene Bunod 0.024% in Patients with Open-Angle Glaucoma Switched from Prior Pharmacotherapy: A Retrospective Chart Review

Overview

Journal Clin Ophthalmol

Publisher Dove Medical Press

Specialty Ophthalmology

Date 2024 Feb 13

PMID 38348139

Authors

Constance O Okeke

Nora Lee Cothran

Desirae A Brinkley

Kamran Rahmatnejad

Frank J Rodino

James E Deom

Affiliations

Soon will be listed here.

Abstract

Introduction: Latanoprostene bunod 0.024% (LBN, Vyzulta) is a nitric oxide-donating prostaglandin analog (PGA). We investigated the real-world efficacy and safety of LBN in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) who switched their existing intraocular pressure (IOP)-lowering treatment(s) to LBN.

Methods: This non-interventional, multicenter (United States), retrospective chart review included patients aged ≥18 years with OHT and/or mild-to-moderate OAG diagnoses taking 1-2 IOP-lowering treatments at the time of switch to LBN (index visit). Chart-extracted data included demographics, diagnoses, IOP and ocular assessments, other IOP-lowering treatments, adverse events (AEs), and reasons for discontinuation. The main study outcome was IOP change from the index visit to each of the next 2 chart-recorded follow-up visits. Analysis groups included the overall dataset and 2 subgroups of patients switched from PGA therapy to LBN: "PGA-all" subgroup [all patients previously on a PGA with/without another IOP-lowering product] and "PGA-monotherapy" subgroup [patients previously on a PGA alone]). Additional ocular outcomes (eg, visual acuity) were examined, if available.

Results: The overall dataset included 49 patients (46 had OAD alone, 2 had OHT alone, and 1 had both). The PGA-all subgroup and PGA-monotherapy subgroups had 41 and 32 patients, respectively. Switching to LBN led to a ~25% IOP reduction from the index visit to Visit 1 that was sustained at Visit 2. IOP findings in the PGA-all and PGA-monotherapy subgroups were consistent with the overall dataset. No meaningful changes in other ocular outcomes were found. Of 14 ocular AEs, 3 were recorded as such (mild in severity, considered unrelated to treatment), and 11 were identified through review of interval ocular histories (no severity/relatedness information); none led to discontinuation.

Conclusion: In this short-term retrospective chart review of mild-to-moderate OAG/OHT, switching prior IOP-lowering therapy to LBN produced an additional ~25% IOP reduction and appeared to be well tolerated.

References

Francis B, Varma R, Chopra V, Lai M, Shtir C, Azen S . Intraocular pressure, central corneal thickness, and prevalence of open-angle glaucoma: the Los Angeles Latino Eye Study. Am J Ophthalmol. 2008; 146(5):741-6. PMC: 2583935. DOI: 10.1016/j.ajo.2008.05.048. View

Medeiros F, Martin K, Peace J, Scassellati Sforzolini B, Vittitow J, Weinreb R . Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: The LUNAR Study. Am J Ophthalmol. 2016; 168:250-259. DOI: 10.1016/j.ajo.2016.05.012. View

Cavet M, DeCory H . The Role of Nitric Oxide in the Intraocular Pressure Lowering Efficacy of Latanoprostene Bunod: Review of Nonclinical Studies. J Ocul Pharmacol Ther. 2017; 34(1-2):52-60. PMC: 5963638. DOI: 10.1089/jop.2016.0188. View

Weinreb R, Liebmann J, Martin K, Kaufman P, Vittitow J . Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings. J Glaucoma. 2017; 27(1):7-15. PMC: 7654727. DOI: 10.1097/IJG.0000000000000831. View

Mehta A, Kanu L, Sood-Mendiratta S, Quinones R, Hawkins A, Lehrer R . Experience with netarsudil 0.02% and latanoprostene bunod 0.024% as adjunctive therapy for glaucoma. Eur J Ophthalmol. 2021; 32(1):322-326. DOI: 10.1177/1120672121998913. View

Wang Y, Liao Y, Nie X . Comparative evaluation of Latanoprostene Bunod, Timolol Maleate, and latanoprost Ophthalmic Solutions to assess their safety and efficacy in lowering intraocular pressure for the management of Open-Angle Glaucoma. Clinics (Sao Paulo). 2020; 75:e1874. PMC: 7688071. DOI: 10.6061/clinics/2020/e1874. View

Weinreb R, Ong T, Scassellati Sforzolini B, Vittitow J, Singh K, Kaufman P . A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study. Br J Ophthalmol. 2014; 99(6):738-45. PMC: 4453588. DOI: 10.1136/bjophthalmol-2014-305908. View

Zhou B, Bekerman V, Khouri A . Use of Latanoprostene Bunod as Adjunctive Glaucoma Therapy in Refractory Glaucoma. J Curr Glaucoma Pract. 2023; 16(3):166-169. PMC: 9905875. DOI: 10.5005/jp-journals-10078-1386. View

Okeke C, Burstein E, Trubnik V, Deom J, Cooper M, Brinkley D . Retrospective Chart Review on Real-World Use of Latanoprostene Bunod 0.024% in Treatment-Naïve Patients with Open-Angle Glaucoma. Ophthalmol Ther. 2020; 9(4):1041-1053. PMC: 7708554. DOI: 10.1007/s40123-020-00307-0. View

10.

Quigley H, Broman A . The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006; 90(3):262-7. PMC: 1856963. DOI: 10.1136/bjo.2005.081224. View

11.

Gupta P, Zhao D, Guallar E, Ko F, Boland M, Friedman D . Prevalence of Glaucoma in the United States: The 2005-2008 National Health and Nutrition Examination Survey. Invest Ophthalmol Vis Sci. 2016; 57(6):2905–2913. PMC: 4868098. DOI: 10.1167/iovs.15-18469. View

12.

Kawase K, Vittitow J, Weinreb R, Araie M . Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study. Adv Ther. 2016; 33(9):1612-27. PMC: 5020123. DOI: 10.1007/s12325-016-0385-7. View

13.

Kass M, Heuer D, Higginbotham E, Johnson C, Keltner J, Miller J . The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002; 120(6):701-13; discussion 829-30. DOI: 10.1001/archopht.120.6.701. View

14.

Flaxman S, Bourne R, Resnikoff S, Ackland P, Braithwaite T, Cicinelli M . Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis. Lancet Glob Health. 2017; 5(12):e1221-e1234. DOI: 10.1016/S2214-109X(17)30393-5. View

15.

Last J, Pan T, Ding Y, Reilly C, Keller K, Acott T . Elastic modulus determination of normal and glaucomatous human trabecular meshwork. Invest Ophthalmol Vis Sci. 2011; 52(5):2147-52. PMC: 3080174. DOI: 10.1167/iovs.10-6342. View

16.

Weinreb R, Scassellati Sforzolini B, Vittitow J, Liebmann J . Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study. Ophthalmology. 2016; 123(5):965-73. DOI: 10.1016/j.ophtha.2016.01.019. View

17.

Radell J, Sharma H, Auyeung K, Paul M, Gagliuso D, Chadha N . Two-Year Experience With Latanoprostene Bunod in Clinical Practice. J Glaucoma. 2021; 30(9):776-780. DOI: 10.1097/IJG.0000000000001904. View

18.

Liu B, McNally S, Kilpatrick J, Jarvis S, OBrien C . Aging and ocular tissue stiffness in glaucoma. Surv Ophthalmol. 2017; 63(1):56-74. DOI: 10.1016/j.survophthal.2017.06.007. View